RT Journal Article
SR Electronic
T1 Impact of BNT162b first vaccination on the immune transcriptome of elderly patients infected with the B.1.351 SARS-CoV-2 variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.11.21256862
DO 10.1101/2021.05.11.21256862
A1 Knabl, Ludwig
A1 Lee, Hye Kyung
A1 Wieser, Manuel
A1 Mur, Anna
A1 Zabernigg, August
A1 Knabl, Ludwig
A1 Rauch, Simon
A1 Bock, Matthias
A1 Schumacher, Jana
A1 Kaiser, Norbert
A1 Furth, Priscilla A.
A1 Hennighausen, Lothar
YR 2021
UL http://medrxiv.org/content/early/2021/05/14/2021.05.11.21256862.abstract
AB Fast-spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) energize the COVID-19 pandemic. The B.1.351 variant carrying the escape mutation E484K in the receptor binding domain is of particular concern due to reduced immunological protection following vaccination. Protection can manifest as early as 10 days following immunization with full protection two weeks following the second dose, but the course is not well-characterized for variants. Here, we investigated the immune transcriptome of six elderly individuals (average age 82 yr.) from an old people’s home, who contracted B.1.351, with four having received the first dose of BNT162b eight to 11 days prior to the onset of COVID-19 symptoms. The patients were hospitalized and received dexamethasone treatment. Immune transcriptomes were established from PBMCs approximately 10 and 35 days after the onset of COVID-19 symptomology. RNA-seq revealed a more intensive immune response in vaccinated patients as compared to unvaccinated ones. Specifically, transcription factors linked to the JAK/STAT pathway, interferon stimulated genes, and genes associated with innate antiviral immunity and COVID-19-SARS-CoV-2 infection were highly enriched in vaccinated patients. This rendered the transcriptomes of the older vaccinated group significantly different than older unvaccinated individuals infected at the same institution and more similar to the immune response of younger unvaccinated individuals (age range 48-62) following B.1.351 infection. All individuals in this study whether vaccinated or not were hospitalized due to B.1.351 infection and one vaccinated patient died illustrating that although an enhanced immune response was documented infection it was insufficient to protect from disease. This highlights the need for maintaining physical distancing and prevention measures throughout the time course of vaccination in older adults.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study was approved by the Institutional Review Board (IRB) of the Office of Research Oversight / Regulatory Affairs, Medical University of Innsbruck, Austria (EC numbers: 1064/2021).Funding StatementThis work was supported by the Intramural Research Programs (IRPs) of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board (IRB) of the Office of Research Oversight / Regulatory Affairs, Medical University of Innsbruck, Austria (EC numbers: 1064/2021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe RNA-seq data of patients will be uploaded in GEO before publishing the manuscript.